PTPN6

Tyrosine-protein phosphatase non-receptor type 6 · P29350 · PTPN6 on Sugi Atlas →

46,310 patent compounds predicted against PTPN6, 28,217 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL305465	0.42	7/20
Oleanolic_Acid (SCHEMBL408433)	0.86	4/20
SCHEMBL330067	0.70	4/20
Tanshinone I (SCHEMBL244391)	1.00	3/20
Echinocystic Acid (SCHEMBL42864)	0.75	3/20
SCHEMBL408434	0.72	3/20
Primulagenin (SCHEMBL179854)	0.63	3/20
Avarol (SCHEMBL186460)	0.62	3/20
SCHEMBL313198	0.55	3/20
Biphenyl (SCHEMBL195288)	0.44	3/20
SCHEMBL163996	0.42	3/20
Ursolic Acid (SCHEMBL70205)	1.00	2/20
Ursolic Acid (SCHEMBL70206)	1.00	2/20
Oleanolic_Acid (SCHEMBL71070)	1.00	2/20
Corosolic Acid (SCHEMBL335528)	1.00	2/20
Hederagenin (SCHEMBL359809)	0.79	2/20
Beta-Amyrin (SCHEMBL377754)	0.76	2/20
SCHEMBL178210	0.73	2/20
SCHEMBL178211	0.73	2/20
Oleanonic Acid (SCHEMBL246220)	0.71	2/20

Clinical trials — most relevant to PTPN6 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Pegylated-Interferon and Ribavirin Plus Metformin in the Treatment of Chronic HCV Infection and Insulin Resistance	PHASE4	UNKNOWN
A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia	PHASE3	RECRUITING
Pembrolizumab and Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma (PICH Study)	PHASE1/PHASE2	WITHDRAWN
Pembrolizumab And Tamoxifen Among Women With Advanced Hormone Receptor Positive Breast Cancer And Esr1 Mutation	PHASE2	UNKNOWN
Pembrolizumab (MK-3475) in MM Patients With Residual Disease	PHASE2	COMPLETED
Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma	PHASE2	RECRUITING
Small Cell Lung Carcinoma Trial With Nivolumab and IpiliMUmab in LImited Disease	PHASE2	COMPLETED
Study in Adult Ph-positive ALL	PHASE2	UNKNOWN
An Exploratory Study on the Use of Ipalotinib (Tislelizumab) Combined With Sunitinib and Olaparib for Neoadjuvant Therapy in HRD-positive Advanced Ovarian Cancer	PHASE2	RECRUITING
TORI 104 Pre-Surgical Dasatinib	PHASE2	WITHDRAWN
Immunoregulatory Therapy for 2019-nCoV	PHASE2	UNKNOWN
SUTENT (SUNITINIB, SU11248)in Patients With Recurrent or Progressive Glioblastoma Multiforme	PHASE2	UNKNOWN
Phase I Study of SC-43 Oral Solution in Subjects With Refractory Solid Tumors	PHASE1	WITHDRAWN
A Study of HMPL-415S1 in Patients With Advanced Malignant Solid Tumors	PHASE1	RECRUITING
Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers	PHASE1	COMPLETED
Lymphoid Tyrosine Phosphatase Gene Polymorphisms in Inflammatory Bowel Disease	nan	UNKNOWN
Uncovering Genes Behind Cartilage Tumors and Vascular Anomalies Using Genomic Sequencing	nan	RECRUITING
Role of NFKBIA and PTPN22 Genes Polymorphism in Acute Rejection Susceptibility After Living Donor Liver Transplantation in Egyptian Patients.	nan	COMPLETED
Immunophenotypic Evaluation of CD305 and CD85d in B-Cell Lymphoid Neoplasms	nan	NOT_YET_RECRUITING
What is the Impact of TKI on Thyroid Function in CML Patients?	nan	NOT_YET_RECRUITING
Resistance to Immunotherapy in Gastric Cancer	nan	UNKNOWN
Monitoring of Breathing Effort Through Pressure Time Product Measurement Using Airway Occlusion Pressure	nan	UNKNOWN
Cytotoxic T Lymphocyte-Associated Antigen-4 (CTLA-4) Gene Single-nucleotide Polymorphism in Primary Immune Thrombocytopenic Purpura in Children	nan	NOT_YET_RECRUITING
Clinical Research for Azacitidine Combined With Low-dose Dasatinib in Maintenance Therapy of Acute Myeloid Leukemia	nan	UNKNOWN
Clinical Study on the Application of PET Probes Targeting DDR2 in the Diagnosis of Interstitial Lung Disease With Cognitive Impairment	nan	NOT_YET_RECRUITING
NGS in Gallbladder Cancer and Response to Treatment	nan	RECRUITING
rT3 and Inflammation in Hashimoto's Thyroiditis	nan	COMPLETED
Cardiovascular Effects of Empagliflozine	nan	UNKNOWN
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma	nan	COMPLETED
Ibrutinib Adapted to Response in Patients With CLL	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a PTPN6 binder may also engage these)

Protein	Name	Similarity
P29351	—	1.000	P29351 →
P81718	—	1.000	P81718 →
P41499	—	0.995	P41499 →
P35235	—	0.995	P35235 →
Q90687	—	0.994	Q90687 →
PTPN11	Tyrosine-protein phosphatase non-receptor type 11	0.993	landscape →
Q03348	—	0.991	Q03348 →
SYK	Tyrosine-protein kinase SYK	0.990	landscape →
P08487	—	0.989	P08487 →
P18052	—	0.989	P18052 →
Q5R607	—	0.988	Q5R607 →
Q641Z2	—	0.987	Q641Z2 →
P22717	—	0.987	P22717 →
F4INY4	—	0.987	F4INY4 →
Q9EQW7	—	0.987	Q9EQW7 →
P24135	—	0.987	P24135 →
DHX30	ATP-dependent RNA helicase DHX30	0.987	landscape →
PTPRA	Receptor-type tyrosine-protein phosphatase alpha	0.987	landscape →
Q0IIK5	—	0.987	Q0IIK5 →
P25799	—	0.987	P25799 →
PLCG2	1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-2	0.987	landscape →
Q641Y8	—	0.987	Q641Y8 →
F4IJK6	—	0.986	F4IJK6 →
P20192	—	0.986	P20192 →
P04157	—	0.985	P04157 →
O15381	—	0.985	O15381 →
Q62940	—	0.985	Q62940 →
DGKA	Diacylglycerol kinase alpha	0.985	landscape →
O35239	—	0.985	O35239 →
Q5I145	—	0.985	Q5I145 →